Craif
Tokyo, Japan· Est.
Craif develops AI-powered, non-invasive cancer detection tests using urine and saliva biomarkers to shift healthcare from treatment to prevention.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $22M
AI Company Overview
Craif develops AI-powered, non-invasive cancer detection tests using urine and saliva biomarkers to shift healthcare from treatment to prevention.
Oncology
Technology Platform
NANO Intelligence Platform (NANO IP®) integrated with AI algorithms (Bio-AI) to decode microRNA and other biomarker signals from body fluids like urine for early cancer detection.
Opportunities
Expansion of the miSignal test to international markets, particularly the U.S., and the development of a first-in-class early detection device for pancreatic cancer, a high-unmet-need area.
Risk Factors
Clinical and regulatory risk associated with validating and gaining approval for its pancreatic cancer detection device; competition in the growing liquid biopsy and multi-cancer early detection (MCED) space.
Competitive Landscape
Competes with other liquid biopsy companies like Exact Sciences, Grail, and Freenome, but differentiates through its focus on urine-based microRNA detection and its proprietary Bio-AI integration for early signal detection.